ArticleCardiovascular and interventional radiology2026
Midterm Outcomes of Venous Leak Embolization in Patients with Venogenic Erectile Dysfunction Unresponsive to Phosphodiesterase-5 Inhibitors.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular therapy for erectile dysfunction: insights from more than 1000 treatments.CVIR endovascular · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study aimed to evaluate the midterm efficacy and safety of venous leak embolization in patients with erectile dysfunction (ED) who did not respond to phosphodiesterase-5 inhibitors.
methodsFrom October 2019 to June 2024, ED patients with venous leakage were included from a prospective, multicenter, all-comers, investigator-initiated registry. A mixture of ethiodized oil and modified cyanoacrylate-based glue n-butyl 2 cyanoacrylate monomer (NBCA) was used as liquid embolic agent. Before embolization, venous leak was classified on computed tomography cavernosography. The primary safety outcome measure was any major adverse event up to 12 weeks after the procedure. The primary feasibility outcome measure was IIEF-15 (International Index of Erectile Function-15) score improvement ≥ 4 points in ≥ 50% of the subjects at up to 3 months, 1 year, and annually thereafter.
resultsOne hundred seventy-five consecutive patients with venous leak were included. Successful venous leak embolization was achieved in 193/194 (99.5%) of cases. Nontarget embolization (pulmonary embolisms) occurred in 3/175 (1.7%) patients. The primary feasibility outcome measure at 9.2 ± 11.3 months was achieved by 82/138 (59.4%) patients. IIEF-15 scores were 31 ± 22 at baseline, 45 ± 35 up to 3 months, and 43 ± 24 at one year. Eighteen of the 175 patients (10.2%) experienced venous leak recurrence (n = 16) or persistence (n = 2) after embolization at 16.1 ± 14.3 months.
conclusionVenous leak embolization was effective at midterm follow-up in the majority of patients. Venous leak recurrence is rare due to venous leak recanalization or new collateral vein formation.
Indexed as
Identifiers
41162635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.